Pfizer (PFE) : Private Wealth Partners scooped up 23,910 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 516,800 shares of Pfizer which is valued at $16,904,528.Pfizer makes up approximately 4.04% of Private Wealth Partners’s portfolio.
Pfizer opened for trading at $32.56 and hit $33 on the upside on Monday, eventually ending the session at $32.8, with a gain of 0.28% or 0.09 points. The heightened volatility saw the trading volume jump to 3,80,66,813 shares. Company has a market cap of $202,840 M.
Other Hedge Funds, Including , Mathes Company boosted its stake in PFE in the latest quarter, The investment management firm added 14,900 additional shares and now holds a total of 37,836 shares of Pfizer which is valued at $1,237,616. Pfizer makes up approx 0.74% of Mathes Company’s portfolio.Crossvault Capital Management reduced its stake in PFE by selling 1,750 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 138,734 shares of PFE which is valued at $4,615,680. Pfizer makes up approx 3.35% of Crossvault Capital Management’s portfolio.Jacobs Coca reduced its stake in PFE by selling 6,548 shares or 3.1% in the most recent quarter. The Hedge Fund company now holds 204,532 shares of PFE which is valued at $6,647,290. Pfizer makes up approx 1.58% of Jacobs Coca’s portfolio.Palisade Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 50,149 shares of Pfizer which is valued at $1,629,843. Pfizer makes up approx 0.32% of Palisade Asset Management’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.